Literature DB >> 33750378

Antitumor activities of Aspiletrein A, a steroidal saponin from Aspidistra letreae, on non-small cell lung cancer cells.

Hien Minh Nguyen1, Hoai Thi Nguyen2, Suthasinee Seephan3, Hang Bich Do1, Huy Truong Nguyen1, Duc Viet Ho4, Varisa Pongrakhananon5,6.   

Abstract

BACKGROUND: Lung cancer is one of the leading causes of death worldwide due to its strong proliferative and metastatic capabilities. The suppression of these aggressive behaviors is of interest in anticancer drug research and discovery. In recent years, many plants have been explored in order to discover new bioactive secondary metabolites to treat cancers or enhance treatment efficiency. Aspiletrein A (AA) is a steroidal saponin isolated from the whole endemic species Aspidistra letreae in Vietnam. Previously, elucidation of the structure of AA and screening of its cytotoxic activity against several cancer cell lines were reported. However, the antitumor activities and mechanisms of action have not yet been elucidated. In this study, we demonstrated the anti-proliferative, anti-migrative and anti-invasive effects of AA on H460, H23 and A549 human lung cancer cells.
METHODS: MTT, wound healing and Transwell invasion assays were used to evaluate the anti-proliferation, anti-migration and anti-invasion effects of AA, respectively. Moreover, the inhibitory effect of AA on the activity of protein kinase B (Akt), a central mediator of cancer properties, and apoptotic regulators in the Bcl-2 family proteins were investigated by Western blotting.
RESULTS: AA exhibits antimetastatic effects in human lung cancer cells through the inhibition of the pAkt/Akt signaling pathway, which in turn resulted in a significant inhibitory effect of AA on the migration and invasion of the examined lung cancer cells.
CONCLUSIONS: Aspiletrein A may be a potent inhibitor of protein kinase B (Akt). Hence, AA could be further explored as a potential antimetastatic lead compound.

Entities:  

Keywords:  Anti-invasion; Anti-migration; Anti-proliferation; Aspidistra letreae; Aspiletrein A; Lung cancer cells

Year:  2021        PMID: 33750378      PMCID: PMC7941985          DOI: 10.1186/s12906-021-03262-w

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  37 in total

Review 1.  Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer.

Authors:  Daniel J Maslyar; Thierry M Jahan; David M Jablons
Journal:  Semin Thorac Cardiovasc Surg       Date:  2004

Review 2.  Akt in cancer: Mediator and more.

Authors:  Sundaramoorthy Revathidevi; Arasambattu Kannan Munirajan
Journal:  Semin Cancer Biol       Date:  2019-06-04       Impact factor: 15.707

Review 3.  Systems Biology of Cancer Metastasis.

Authors:  Yasir Suhail; Margo P Cain; Kiran Vanaja; Paul A Kurywchak; Andre Levchenko; Raghu Kalluri
Journal:  Cell Syst       Date:  2019-08-28       Impact factor: 10.304

Review 4.  Non-small cell lung cancer: current treatment and future advances.

Authors:  Cecilia Zappa; Shaker A Mousa
Journal:  Transl Lung Cancer Res       Date:  2016-06

5.  Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.

Authors:  Haiying Cheng; Marina Shcherba; Gopichand Pendurti; Yuanxin Liang; Bilal Piperdi; Roman Perez-Soler
Journal:  Lung Cancer Manag       Date:  2014-01-01

Review 6.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

7.  Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data.

Authors:  Manish K Thakur; Julie J Ruterbusch; Ann G Schwartz; Shirish M Gadgeel; Jennifer L Beebe-Dimmer; Antoinette J Wozniak
Journal:  J Thorac Oncol       Date:  2017-10-05       Impact factor: 15.609

8.  Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.

Authors:  Pasquale Comella; Vincenzo E Chiuri; Giuseppe De Cataldis; Gianfranco Filippelli; Luigi Maiorino; Giacomo Vessia; Riccardo Cioffi; Sergio Mancarella; Carlo Putzu; Ettore Greco; Laura Palmeri; Raffaele Costanzo; Antonio Avallone; Luca Franco
Journal:  Lung Cancer       Date:  2009-07-09       Impact factor: 5.705

9.  Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.

Authors:  Rafael Santana-Davila; Aniko Szabo; Carlos Arce-Lara; Christina D Williams; Michael J Kelley; Jeff Whittle
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

10.  Moscatilin inhibits lung cancer cell motility and invasion via suppression of endogenous reactive oxygen species.

Authors:  Akkarawut Kowitdamrong; Pithi Chanvorachote; Boonchoo Sritularak; Varisa Pongrakhananon
Journal:  Biomed Res Int       Date:  2013-05-08       Impact factor: 3.411

View more
  1 in total

1.  Aspiletrein A Induces Apoptosis Cell Death via Increasing Reactive Oxygen Species Generation and AMPK Activation in Non-Small-Cell Lung Cancer Cells.

Authors:  Wasita Witayateeraporn; Hien Minh Nguyen; Duc Viet Ho; Hoai Thi Nguyen; Pithi Chanvorachote; Chanida Vinayanuwattikun; Varisa Pongrakhananon
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.